Diagon Therapeutics

Diagon Therapeutics is a biotechnology company pioneering a new class of medicines designed to restore cellular proteostasis by modulating the chaperone system. The company’s platform targets the underlying protein misfolding and aggregation that drive a variety of devastating diseases, particularly in the neurodegenerative space. By enhancing the cell's innate capacity to fold or degrade proteins, Diagon aims to develop disease-modifying therapies for conditions such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s disease. Headquartered in Cambridge, Massachusetts, the company is backed by leading life science investors including 5AM Ventures and Frazier Life Sciences. Its approach leverages foundational research into the 'chaperome' to identify novel small molecule modulators.